Evidence map›Paper›PMID 40116780›Full record

ArticleCancer biomarkers : section A of Disease markers2025

Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening.

Kristina R Dahlstrom, Andrew T Day, Victor M Alvarez, Samantha R Chirinos, Giselle Santillana, Ming Guo, Karen S Anderson, Erich M Sturgis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kristina R DahlstromSection of Epidemiology & Population Sciences - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-8116-9558
Andrew T DayDepartment of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-7187-4125
Victor M AlvarezDepartment of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Samantha R ChirinosDepartment of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Giselle SantillanaDepartment of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Ming GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6773-1145
Karen S AndersonBiodesign Institute, Arizona State University, Tempe, Arizona, USA.ORCID 0000-0002-3870-5730
Erich M SturgisDepartment of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-1069-4822

Funding

Southwest EDRN Clinical Validation Center for Head and Neck CancerU01CA281660 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Karen Sue Anderson, Kristina Dahlstrom · 2023 to 2026
$3.7M
NCI NIH HHS U01 CA281660
6 · The paper itself

Abstract

BackgroundOropharyngeal cancer rates continue to rise with no effective screening method. Persistent oral oncogenic human papillomavirus (HPV), antibodies to HPV16 early (E) oncoproteins, and circulating tumor HPV DNA (ctHPVDNA) are biomarkers that show promise for use in HPV-related cancer screening.ObjectiveTo assess the prevalence of biomarkers for HPV-related cancer and their agreement in middle-aged men.MethodsMen aged 50-64 years from the general population provided oral rinse and blood samples as well as information about demographics, tobacco/alcohol exposure, sexual behavior, and HPV-related disease history. Oral rinse was tested for HPV16 DNA and plasma was tested for HPV16 E antibodies and ctHPVDNA using a droplet digital PCR (ddPCR)-based assay that measures circulating tumor tissue modified viral (TTMV)-HPV DNA (NavDx, Naveris, Inc.). We calculated frequency distributions of variables of interest and agreement between the biomarkers.ResultsWe enrolled 1045 subjects between April 2017 and April 2024. The 954 subjects with results for all three biomarkers were included in the analysis. The prevalence was 4.9% for oral HPV16 DNA, 0.7% for HPV16 E antibodies, and 0.5% for TTMV-HPV DNA.ConclusionsThe low prevalence of all three biomarkers shows their potential to identify high-risk individuals eligible for further clinical HPV-related cancer screening.

Indexed as

Antibodies, ViralBiomarkers, TumorCirculating Tumor DNADNA, ViralHuman papillomavirus 16Oncogene Proteins, ViralOropharyngeal NeoplasmsPapillomavirus InfectionsEarly Detection of CancerHumansMaleMiddle AgedAntibodies, ViralBiomarkers, TumorCirculating Tumor DNADNA, ViralOncogene Proteins, ViralbiomarkerCancer screeningcirculating tumor tissue modified HPV DNAhead and neck neoplasmsHPV16 antibodieshuman papillomavirusoropharyngeal cancer

Identifiers

PMID40116780
PMCPMC12288378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.